Tivic Health Systems Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing late-stage immune therapies, with Entolimod leading in ARS and neutropenia. Phase III data supports regulatory filings, and government partnerships may enable stockpile inclusion. Key milestones are expected within 18-24 months.
-
The meeting detailed a transformative acquisition of manufacturing assets, enabling in-house production and the launch of Velocity Bioworks as a CDMO. Strategic plans focus on accelerating Entolimod's commercialization, expanding revenue streams, and leveraging new capabilities for both internal and third-party clients.
-
A major transformation has positioned the company as a biopharma with late-stage assets, notably Entolimod, targeting both acute radiation syndrome and oncology. Manufacturing is now in-house, with strong government engagement and up to $75 million in new financing.
-
A major acquisition enabled in-house manufacturing, accelerating drug development and reducing costs while launching Velocity BioWorks as a new revenue-generating CDMO. Positioned for rapid growth, the company expects significant value creation and government engagement in 2026.
Fiscal Year 2025
-
Pivoted to immunotherapy, exited legacy businesses, and acquired in-house manufacturing. Operating expenses rose with the biopharma launch, but cash position improved. Positioned for growth in oncology and biodefense markets, with significant financing secured.
-
Strategic transformation advanced with a shift to biologics, highlighted by Entolimod's clinical progress and government engagement. Q3 saw higher R&D spending, a widened net loss, and improved cash position, with consumer device operations wound down.
-
Significant transformation has integrated late-stage biopharma assets, notably Entolimod, a phase three TLR5 agonist targeting radiation and cancer markets. Manufacturing and regulatory milestones are progressing, supported by strong funding and an experienced team.
-
Expanded into biopharma with exclusive rights to late-stage drug Entolimod, shifting focus from consumer devices. Q2 revenue declined due to reduced ClearUP sales, but gross margins improved; net loss widened as R&D spending increased. Raised $0.9M post-quarter, with $7M more available.
-
A late-stage immunotherapeutics company has rapidly diversified its portfolio, licensing a phase III asset with strong government backing and advancing both biologic and bioelectronic therapies. Multiple regulatory and commercial milestones are expected in the next 18 months.
-
Aggressive transformation has created a diversified immunotherapeutics platform, highlighted by a phase three TLR5 program targeting acute radiation syndrome and a non-invasive VNS device. Government stockpile orders and large oncology markets offer significant revenue potential, with a stable financial position supporting near-term growth.
-
Q1 2025 marked a strategic shift to immunotherapeutics, highlighted by the licensing of Entolimod and Entalasta, improved gross margins, and new financing to support clinical and commercialization milestones. Revenue declined due to reduced D2C focus, but the pipeline and capital position strengthened.
Fiscal Year 2024
-
Secured exclusive rights to late-stage drug Entolimod and expanded into biopharma, while advancing non-invasive VNS technology. Revenue declined due to lower ClearUP sales, but net loss narrowed and a $25M equity line was secured to fund growth.
-
Q3 revenue declined 27% year-over-year, but gross margin for ClearUP improved post-relaunch. Focus is shifting to the high-growth VNS market, with clinical trials progressing and cost reductions supporting a 20% lower net operating loss.
-
Tivic Health Systems presented at a major healthcare conference, highlighting its FDA-approved sinus device and promising non-invasive vagus nerve stimulation platform. The company is advancing clinical development, targeting multiple high-value indications, and expects significant growth and R&D milestones ahead.
-
Q2 2024 saw reduced ClearUP sales but improved gross margins and lower operating expenses, with a net loss narrowing year-over-year. The company completed a $4M offering, advanced its non-invasive VNS program with strong phase I results, and is shifting focus to high-value bioelectronic medicine.